兰索拉唑、克拉霉素、甲硝唑三联疗法治疗幽门螺杆菌相关性溃疡病疗效观察

目的探讨兰索拉唑、克拉霉素、甲硝唑三联疗法治疗幽门螺杆菌相关性溃疡病的效果。方法对51例确诊为幽门螺杆菌(Hp)感染的胃溃疡、十二指肠溃疡患者利用兰索拉唑、克拉霉素、甲硝唑三联疗法进行治疗,观察溃疡愈合情况及Hp根除情况。结果本疗法对溃疡的总有效率为90%,Hp根除率为88%。结论兰索拉唑、克拉霉素、甲硝唑三联疗法治疗幽门螺杆菌相关性溃疡具有药物剂量小、Hp根除率高、溃疡愈合迅速、疗程短等优点,值得在临床上推广应用。

CLINICAL OBSERVATION OF TRIPLE THERAPY REGIMEN WITHLANSOPRAZOLE, CLARITHROMYCIN AND METRONIDAZOLE FOR TREATMENT OF HELICOBACTER PYLORI-RELATED ULCER

Objective To investigate therapeutic effects of triple therapy combined Lansoprazole, clarithromycin and metronidazole for eradicating Helicobacter pylori-related ulcer. Methods Fivty-one patients with H. pylori-infected stomach ulcer or duodenal ulcer received the treatment of triple therapy regimen with lansoprazole, clarithromycin and metronidazole.the efficacy of ulcer healing and hp eradication were observed. Results the cure rate of the triple therapy was 90%,and the eradication rate of H. pylori was 88%.Conclusions Triple therapy using combined Lansoprazole, clarithromycin and metronidazole is worthy of clinical application for curing pylori - infected peptic ulcer accompanied by the lower does, the higher hp eradication rate, ulcer healing more rapidly and the shorter course of treatment.